...
首页> 外文期刊>Hepatology international >A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.
【24h】

A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.

机译:慢性感染不同临床阶段患者乙肝病毒标志物的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Hepatitis B viral markers may be useful for predicting outcomes such as liver-related deaths or development of hepatocellular carcinoma. We determined the frequency of these markers in different clinical stages of chronic hepatitis B infection. METHODS: We compared baseline hepatitis B viral markers in 317 patients who were enrolled in a prospective study and identified the frequency of these tests in immune-tolerant (IT) patients, in inactive carriers, and in patients with either hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis or cirrhosis. RESULTS: IT patients were youngest (median age 27 years) and HBeAg-negative patients with cirrhosis were oldest (median age 58 years) (p = 0.03 to <0.0001). The male to female ratio was similar both in IT patients and in inactive carriers, but there was a male preponderance both in patients with chronic hepatitis and in patients with cirrhosis (p < 0.0001). The A1896 precore mutants were most prevalent in inactive carriers (36.4%) and HBeAg-negative patients with chronic hepatitis (38.8%; p < 0.0001), and the T1762/A1764 basal core promoter mutants were most often detected in HBeAg-negative patients with cirrhosis (65.1%; p = 0.02). Genotype A was detected only in 5.3% of IT patients, and genotype B was least often detected in both HBeAg-Positive patients with chronic hepatitis and cirrhosis (p = 0.03). The hepatitis B viral DNA levels were lowest in inactive carriers (2.69 log(10) IU/mL) and highest in IT patients (6.80 log(10) IU/mL; p = 0.02 to <0.0001). At follow-up, HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for 57 of 64 (89.1%) liver-related deaths (p < 0.0001). CONCLUSION: Differences in baseline hepatitis B viral markers were detected in patients in various clinical stages of hepatitis B virus infection. HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for the majority of the liver-related fatalities.
机译:目的:乙型肝炎病毒标志物可用于预测结局,例如与肝有关的死亡或肝细胞癌的发展。我们确定了在慢性乙型肝炎感染的不同临床阶段中这些标志物的频率。方法:我们比较了参加一项前瞻性研究的317例患者的基线乙型肝炎病毒标志物,并确定了免疫耐受(IT)患者,无活性携带者和乙型肝炎e抗原(HBeAg)患者的检测频率)阳性或HBeAg阴性的慢性肝炎或肝硬化。结果:IT患者最年轻(中位年龄27岁),HBeAg阴性肝硬化患者最老(中位年龄58岁)(p = 0.03至<0.0001)。在IT患者和不活动的携带者中,男女比例相似,但在慢性肝炎和肝硬化患者中,男性占多数(p <0.0001)。 A1896 precore突变体在非活动携带者中占最高比例(36.4%),在慢性乙型肝炎的HBeAg阴性患者中(38.8%; p <0.0001),T1762 / A1764基础核心启动子突变体在HBeAg阴性患者中最常见。肝硬化(65.1%; p = 0.02)。仅在5.3%的IT患者中检测到基因型A,而在慢性乙型肝炎和肝硬化的HBeAg阳性患者中,基因型B的检测率最低(p = 0.03)。乙型肝炎病毒DNA水平在非活动携带者中最低(2.69 log(10)IU / mL),在IT患者中最高(6.80 log(10)IU / mL; p = 0.02至<0.0001)。随访中,肝硬化的HBeAg阳性和HBeAg阴性的患者占64例肝相关死亡中的57例(89.1%)(p <0.0001)。结论:在不同临床阶段的乙型肝炎病毒感染患者中,基线乙型肝炎病毒标志物存在差异。肝硬化的HBeAg阳性和HBeAg阴性患者占大多数与肝有关的死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号